Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyprenorphine is a synthetic opioid compound and a derivative of the morphinan class. It acts as a highly potent mixed agonist–antagonist at opioid receptors. Cyprenorphine is primarily known for its strong antagonistic activity at opioid receptors—blocking the effects of opioids such as morphine and etorphine—and is roughly 35 times more potent than nalorphine as an antagonist. While it has some agonist properties similar to buprenorphine and diprenorphine (to which it is structurally related), cyprenorphine produces pronounced dysphoric and hallucinogenic effects that limit its use in humans. Its main application has been in veterinary medicine to reverse the immobilizing effects of etorphine in large animals after procedures. The drug induces psychotomimetic side effects in humans and has no accepted medical use due to safety concerns[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyprenorphine.